Randomized Trial of Osilodrostat for the Treatment of Cushing Disease
Open accessThe DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Context: Cushing disease, a chronic hypercortisolism disorder, is associated with considerable morbidity and mortality. Normalizing cortisol production is the primary treatment goal. Objective: We aimed to evaluate the safety and efficacy of osilodrostat, a potent, orally available 11βhydroxylase inhibitor, compared with placebo in patients with Cushing disease. Methods: LINC 4 was a phase III, multicenter trial comprising an initial 12-week, randomized, double-blind, placebo-controlled (osilodrostat:placebo, 2:1) period followed by a 36-week, open-label treatment period (NCT02697734). Adult patients (aged 18-75 years) with confirmed Cushing disease and mean urinary free cortisol (mUFC) excretion ≥ 1.3 times the upper limit of normal (ULN) were eligible. The primary endpoint was the proportion of randomized patients with mUFC ≤ ULN at week 12. The key secondary endpoint was the proportion achieving mUFC ≤ ULN at week 36 (after 24 weeks’ open-label osilodrostat). Results: Seventy-three patients (median age, 39 years [range, 19-67]; mean/median mUFC, 3.1 × ULN/2.5 × ULN) received randomized treatment with osilodrostat (n = 48) or placebo (n = 25). At week 12, significantly more osilodrostat (77%) than placebo (8%) patients achieved mUFC ≤ ULN (odds ratio 43.4; 95% CI 7.1, 343.2; P < 0.0001). Response was maintained at week 36, when 81% (95% CI 69.9, 89.1) of all patients achieved mUFC ≤ ULN. The most common adverse events during the placebo-controlled period (osilodrostat vs placebo) were decreased appetite (37.5% vs 16.0%), arthralgia (35.4% vs 8.0%), and nausea (31.3% vs 12.0%). Conclusion: Osilodrostat rapidly normalized mUFC excretion in most patients with Cushing disease and maintained this effect throughout the study. The safety profile was favorable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The restoration of cortisol circadian rhythm following medical therapy has not been investigated or established for most medications used to treat CS, and it is not routinely measured to determine treatment response (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [134]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mean UFC is routinely used in clinical practice and research to monitor disease control and treatment response in patients with CS treated with medical therapy (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In clinical trials, the efficacy of steroidogenesis inhibitors and pituitary-directed therapies in patients with CS was primarily evaluated by the normalization of cortisol secretion per UFC (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationTreatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953 · cited 4×
“However, up to onethird of patients do not achieve sustained remission after pituitary surgery and require additional treatment (3, 5).”
BackgroundInfluentialSelf-citationTreatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641 · cited 1×
“Prolonged exposure to elevated cortisol levels is associated with substantial morbidity and mortality and impaired quality of life (QoL) (1-3).”
BackgroundThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Daniel, E., Aylwin, S., Mustafa, O., Ball, S., Munir, A., Boelaert, K., Chortis, V., Cuthbertson, D. J., Daousi, C., Rajeev, S. P., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2616 · Cited by 231 · cited 1×
“6 years; dose schedule: 2–4 doses/day) in patients with Cushing’s syndrome (n=115/164 had Cushing’s disease), 43% of 37 patients with mUFC measurements available had normalized mUFC (17).”
BackgroundWebb, S. M., Badia, X., Barahona, M. J., Colao, A., Strasburger, C. J., Tabarin, A., van Aken, M. O., Pivonello, R., Stalla, G., Lamberts, S. W. J., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0762 · Cited by 229 · cited 1×
“12 scale for facial rubor, striae, supraclavicular fat pad, dorsal fat pad, proximal muscle wasting, abdominal obesity, and bruising; and change in health-related QoL, assessed using the Cushing’s Disease Health-Related Quality of Life Questionnaire (CushingQoL) (11) and the Beck Depression Inventory second edition (B…”
MethodPivonello, R., Fleseriu, M., Newell-Price, J., Bertagna, X., Findling, J., Shimatsu, A., Gu, F., Auchus, R., Leelawattana, R., Lee, E. J., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30240-0 · Cited by 222
Self-citation(2007) · Encyclopedia of Measurement and Statistics · doi:10.4135/9781412952644.n49 · Cited by 190
Cited by
Reincke, M., & Fleseriu, M. (2023) · JAMA · doi:10.1001/jama.2023.11305 · Cited by 256
Gadelha, M., Gatto, F., Wildemberg, L. E., & Fleseriu, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01961-x · Cited by 168
Self-citationDormoy, A., Haissaguerre, M., Vitellius, G., Cao, C. D., Geslot, A., Drui, D., Lasolle, H., Vieira-Pinto, O., Salenave, S., François, M., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac691 · Cited by 82
An individualized approach to the management of Cushing disease
Fleseriu, M., Varlamov, E. V., Hinojosa‐Amaya, J. M., Langlois, F., & Melmed, S. K. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00868-7 · Cited by 80
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension
Fleseriu, M., Newell-Price, J. D. C., Pivonello, R., Shimatsu, A., Auchus, R. J., Scaroni, C. M., Belaya, Z. E., Feelders, R. A., Vila, G., Houde, G., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0317 · Cited by 78
Self-citationAldosterone and aldosterone synthase inhibitors in cardiorenal disease
Verma, S., Pandey, A., Pandey, A. K., Butler, J., Lee, J. S., Teoh, H., Mazer, C. D., Kosiborod, M., Cosentino, F., Anker, S. D., et al. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00419.2023 · Cited by 76
Fleseriu, M., & Biller, B. M. K. (2022) · Pituitary · doi:10.1007/s11102-022-01268-2 · Cited by 54
Cushing’s disease: adrenal steroidogenesis inhibitors
Pivonello, R., Simeoli, C., Paola, N. D., & Colao, A. (2022) · Pituitary · doi:10.1007/s11102-022-01262-8 · Cited by 58
“1% of the 48 patients randomly assigned to receive osilodrostat versus 8% of the 25 patients randomly assigned to receive placebo [23].”
BackgroundMethodAldosterone and Aldosterone Modulation in Cardio-Kidney Diseases
Fioretti, F., Testani, J. M., Tio, M. C., Pitt, B., & Butler, J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.012 · Cited by 56
Gadelha, M. R., Snyder, P. J., Witek, P., Bex, M., Belaya, Z. E., Turcu, A. F., Feelders, R. A., Heaney, A. P., Paul, M., Pedroncelli, A. M., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1236465 · Cited by 51
“There were no escape-from-response events during the extension phase following the primary analysis cut-off (February 25, 2020) (13).”
BackgroundMethodInfluentialSelf-citationFleseriu, M., Biller, B. M. K., Bertherat, J. Y., Young, J., Hatipoğlu, B., Arnaldi, G., O'Connell, P. R., Izquierdo, M. A., Pedroncelli, A. M., & Pivonello, R. (2022) · Pituitary · doi:10.1007/s11102-022-01280-6 · Cited by 45
“The clinical benefits observed in this analysis are consistent with data from LINC 4, which showed that improvements in most cardiovascular-related parameters from baseline were first observed during the initial 12-week dose-titration period and were maintained up to the end of the core study (week 48) [17].”
ResultSelf-citationBaxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension
Dogra, S., Shah, S., GITZEL, L., Pusukur, B., Sood, A., Vyas, A. V., & Gupta, R. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101918 · Cited by 37
Treatment of Cushing Disease With Pituitary-Targeting Seliciclib
Liu, N., Ben-Shlomo, A., Carmichael, J. D., Wang, C., Swerdloff, R. S., Heaney, A. P., Barkhoudarian, G., Kelly, D. F., Noureddin, M., Lü, L., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac588 · Cited by 32
Self-citationClinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature
Perosevic, M., & Tritos, N. A. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s315359 · Cited by 32
“0001).(9,27) As expected, plasma aldosterone levels decreased and the levels of steroid precursors, including 11-deoxycortisol and 11deoxycorticosterone, increased.”
BackgroundFerrari, D., Bonaventura, I., Simeoli, C., Tomaselli, A., Vincenzi, L., De Alcubierre, D., Sciarra, F., Rizzo, F., Cerroni, L., Di Paola, N., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf206 · Cited by 28
Pharmacological Treatment of Cushing's Syndrome
Castinetti, F. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102908 · Cited by 33
Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
Mazzieri, A., Timio, F., Patera, F., Trepiccione, F., Bonomini, M., & Reboldi, G. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000542621 · Cited by 29
“Two phase III pivotal trials, the LINC 3 [91] and LINC 4 [92], tested the ef fi cacy of osilodrostat in patients with nonsurgical Cushing ’ s disease.”
Fleseriu, M., Pivonello, R., Newell-Price, J. D. C., Gadelha, M. R., Biller, B. M. K., Auchus, R. J., Feelders, R. A., Shimatsu, A., Witek, P., Bex, M., et al. (2025) · Pituitary · doi:10.1007/s11102-024-01471-3 · Cited by 26
“Safety data have been published previously [ 19, 20, 24, 25 ].”
InfluentialSelf-citationNewell-Price, J., Fleseriu, M., Pivonello, R., Feelders, R. A., Gadelha, M. R., Lacroix, A., Witek, P., Heaney, A. P., Piacentini, A., Pedroncelli, A. M., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae201 · Cited by 21
“…indicating the accumulation of adrenal hormone precursors or subsequent increases in androgen levels (elevated blood testosterone in women, acne, hirsutism in women, peripheral edema, hypertension, and hypokalemia [17]) and for QT-interval prolongation or changes in arrhythmogenic potential.”
InfluentialSelf-citationDziałach, Ł., Sobolewska, J., Respondek, W., Wojciechowska-Luźniak, A., & Witek, P. (2022) · HORMONES · doi:10.1007/s42000-022-00397-4 · Cited by 24
“In a phase III study (LINC 4) in patients with CD, osilodrostat normalized UFC excretion in 77% of patients after 12 weeks’ treatment [20].”
BackgroundSelf-citationSelectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450
Valentín-Goyco, J., Liu, J., Peng, H., Oommen, J., & Auchus, R. J. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106316 · Cited by 27
Self-citationShimatsu, A., Biller, B. M. K., Fleseriu, M., Pivonello, R., Lee, E. J., Leelawattana, R., Kim, J. H., Walia, R., Yu, Y., Liao, Z., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0153 · Cited by 25
Self-citationMohammedi, K., Bertherat, J. Y., Raverot, G., Drui, D., Reznik, Y., Castinetti, F., Chanson, P., Manon, F., Brossaud, J., & Tabarin, A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad251 · Cited by 21
Pivonello, R., Simeoli, C., Paola, N. D., Larocca, A., Crescenzo, E. M., & Colao, A. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.1.8 · Cited by 21
“1–4,6 1–6 However, some specific safety issues should be considered in clinical practice and herein will be discussed.”
BackgroundFleseriu, M., Auchus, R. J., Bancos, I., & Biller, B. M. K. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf027 · Cited by 23
“AI may have been mitigated by slower titration, as shown in LINC 4 vs 3 [43, 45].”
InfluentialSelf-citationUpdate and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome
Araujo-Castro, M., Lamas, C., Nowak, E., Newell-Price, J. D. C., Reincke, M., & Castinetti, F. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf042 · Cited by 24
Fleseriu, M., Auchus, R. J., Huang, W., Spencer-Segal, J. L., Yuen, K. C. J., Dacus, K. C., Padgett, J., Babler, E. K., Das, A. K., Campos, C. R., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf046 · Cited by 16
“Slower dose escalation may reduce the risk of hypocortisolism-related AEs; the longer titration interval in LINC 4 (every 3 weeks) than in LINC 3 (every 2 weeks) may explain the lower incidence of hypocortisolism-related AEs during LINC 4 [10, 12].”
InfluentialSelf-citationMedical treatment of Cushing’s disease with concurrent diabetes mellitus
Mehlich, A., Bolanowski, M., Mehlich, D., & Witek, P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1174119 · Cited by 16
“In patients who were not classified as diabetic at baseline, fasting plasma glucose and HbA1c levels remained within the normal range and were stable throughout the treatment (113).”
BackgroundSelf-citationStructural and clinical characterization of CYP11B2 inhibition by dexfadrostat phosphate
Pignatti, E., Kollár, J., Hafele, E., Schuster, D., Steele, R. E., Vogt, B., Schumacher, C., & Groessl, M. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106409 · Cited by 13
“A third compound, osilodrostat, has been characterized as a potent 11 β -hydroxylase inhibitor and successfully developed for Cushing ’ s Disease [30].”
BackgroundNagendra, L., Dutta, D., Raizada, N., Surana, V., Selvan, C., & Bhattacharya, S. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_260_23 · Cited by 11
“[4,5] Studies by Bertagna et al . and Fleseriu et al .”
BackgroundFano, M. D., Falorni, A., Malara, M., Porcellati, F., & Fanelli, C. G. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s466328 · Cited by 14
Medical management pathways for Cushing’s disease in pituitary tumors centers of excellence (PTCOEs)
Giustina, A., Uygur, M. M., Frara, S., Barkan, A. L., Biermasz, N. R., Chanson, P., Freda, P. U., Gadelha, M. R., Haberbosch, L., Kaiser, U. B., et al. (2025) · Pituitary · doi:10.1007/s11102-024-01485-x · Cited by 13
Self-citationHow best to monitor the specific side effects of medical treatments of Cushing’s disease
Castinetti, F. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101718 · Cited by 12
Advances in Molecular Pathophysiology and Targeted Therapy for Cushing’s Disease
Takayasu, S., Kageyama, K., & Daimon, M. (2023) · Cancers · doi:10.3390/cancers15020496 · Cited by 15
Działach, Ł., Sobolewska, J., Respondek, W., Szamotulska, K., & Witek, P. (2023) · Biomedicines · doi:10.3390/biomedicines11123227 · Cited by 10
“Nevertheless, hirsutism in most CD females during osilodrostat treatment improves or remains stable from baseline [18,24].”
BackgroundInfluentialSelf-citationMedical treatment of functional pituitary adenomas, trials and tribulations
Capatina, C. A.-M., Hanzu, F. A., Hinojosa‐Amaya, J. M., & Fleseriu, M. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04670-x · Cited by 11
“A higher rate of 81% was observed at 36 weeks in another randomized placebo-controlled period phase III trial [105].”
Pivonello, R., Scaroni, C. M., Polistena, B., Migliore, A., & Giustina, A. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02058-8 · Cited by 15
Samson, S. L., Donegan, D. M., Geer, E. B., Gordon, M. B., Hamidi, O., Huang, W., Ioachimescu, A. G., Silverstein, J. M., Spencer-Segal, J. L., Tritos, N. A., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf103 · Cited by 9
“Results from the LINC 4 clinical study suggested that hypoadrenal adverse effects can be mitigated with slower titration [30], but there is still a need for additional guidance on how to utilize osilodrostat optimally during dose titration and when symptoms and un-planned events arise (eg,…”
Update on Medical Treatment of Cushing’s Syndrome
Dillon, B. R., Agrawal, N., Schwarz, Y., Dancel-Manning, K., Tabarin, A., Lacroix, A., Hofland, L. J., & Feelders, R. A. (2025) · Drugs · doi:10.1007/s40265-025-02223-8 · Cited by 13
“In prospective, randomized, phase 3 studies conducted in participants with CD, UFC normalization occurred in up to 81% after 12 weeks with sustained control [71, 72].”
InfluentialSelf-citationHow to manage Cushing's disease after failed primary pituitary surgery
Agrawal, N., Urwyler, S. A., Mehta, S., Karavitaki, N., & Feelders, R. A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae110 · Cited by 8
Self-citationGamrat-Żmuda, A., Minasyan, M., Wysocki, P. J., Hubalewska–Dydejczyk, A., & Gilis‐Januszewska, A. (2025) · Cancers · doi:10.3390/cancers17101611 · Cited by 8
Self-citationFleseriu, M., Pivonello, R., Lacroix, A., Biller, B. M. K., Feelders, R. A., Gadelha, M. R., Bertherat, J. Y., Belaya, Z. E., Piacentini, A., Pedroncelli, A. M., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf207 · Cited by 11
Self-citationLee, K. A., Pessoa, C. M., & Huang, W. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luae255 · Cited by 11
“Osilodrostat inhibits 11-beta hydroxylase, and its efficacy and safety has been demonstrated in the treatment of Cushing disease [18, 19].”
Antonini, S., Brunetti, A., Zampetti, B., Boeris, D., Saladino, A., & Cozzi, R. C. (2022) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-22-0311 · Cited by 7
Paes, T., van der Pas, R., van Koetsveld, P. M., Dogan, F., van den Berge, K. K. A., Netea-Maier, R. T., Bisschop, P. H. L. T., Hofland, L. J., & Feelders, R. A. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf089 · Cited by 6
Self-citationApproach to the Patient With Cyclical Cushing Syndrome
Ferrière, A., Nunes, M. L., & Tabarin, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae864 · Cited by 9
Castro, M. A., García-Centeno, R., Fernández, L. G., Hanzu, F. A., Orois, A., Cámara, R., García, M. D. O., Irigaray, A., Gimeno, P. G., Corrales, E. P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217575 · Cited by 8
Castro, M. A., García-Centeno, R., Fernández, L. G., Soto‐Moreno, A., Cámara, R., García, M. D. O., Irigaray, A., Gracia, P., Corrales, E. P., Biagetti, B., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02769-0 · Cited by 7
Discontinuation of Drug Treatment in Cushing's Disease Not Cured by Pituitary Surgery
Ghalawinji, A., Drezet, L., Chaffanjon, P. C., Muller, M., Stürm, N., Simiand, A., Lazard, A., Gay, E., Chabre, O., & Cristante, J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad662 · Cited by 6
How often should we perform magnetic resonance imaging (MRI) for the follow-up of pituitary adenoma?
Constantinescu, S. M., Duprez, T. P. J., Bonneville, J., & Maiter, D. M. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.03.004 · Cited by 7
Cushing's Syndrome in the Elderly
Zdrojowy-Wełna, A., & Valassi, E. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2317-8821 · Cited by 10
“Osilodrostat, a recently introduced 11βhydroxylase inhibitor, was effective in nor - malizing hypercortisolemia also with a favorable safety profile; however, the trials included only patients below 70 years of age [53, 54].”
BackgroundUnveiling novel molecules and therapeutic targets in hypertension – A narrative review
Jefry Winner, G., Jain, S., & Gupta, D. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177053 · Cited by 6
Medical Treatment of Cushing’s Syndrome
Guignat, L., & Bertherat, J. Y. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.501 · Cited by 9
“…IN Cushing’s (LINC) 4 study—a randomized, double-blind, placebo-controlled trial—76.2% (32/42) of patients without a history of pituitary irradiation achieved disease control, as indicated by normalization of UFC, after 12 weeks of treatment, compared to only 4.5% (1/22) in the placebo group [42].”
InfluentialPiazzola, C., Castinetti, F., von Fabeck, K., & Simon, N. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf185 · Cited by 5
Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome
Tabarin, A., Bertherat, J. Y., Decoudier, B., Lasolle, H., Lefèbvre, H., Drui, D., Vaillant, C., Morera, J., Castinetti, F., Cristante, J., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf633 · Cited by 11
Działach, Ł., Respondek, W., Siejka, A., & Witek, P. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1629387 · Cited by 5
“However, a nearly equal proportion of delayed AI has also been reported across studies (5, 6, 10).”
InfluentialSelf-citationResponse to Osilodrostat Therapy in Adrenal Cushing’s Syndrome
Stasiak, M., Witek, P., Adamska-Fita, E., & Lewiñski, A. (2024) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s453105 · Cited by 4
“1,2 6 More data are available for metyrapone efficacy and safety in CSA, 7 as the drug has been available much longer than osilodrostat.”
BackgroundSelf-citationHickey, C., Gueron, B., Schmidt, F., Tyas, E., Binowski, G., & Pivonello, R. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03229-0 · Cited by 5
“LINC-4 was a Phase III, randomized, double-blind, placebo-controlled study investigating the safety and efficacy of osilodrostat in patients with CD [17].”
Detomas, M., Deutschbein, T., & Altieri, B. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2317-0801 · Cited by 7
“[3,8,11,12,14,47] Osilodrostat Oral 4–60 mg/day 66–100 % [4,14–16,39] Fatigue (29–58 %), nausea (32–42 %), headache (25–34 %), diarrhea (25–32 %), adrenal insufficiency (28–32 %), QT prolongation (4–13 %), and hypertension (12”
BackgroundInfluentialNew Approaches to the Treatment of Hypercortisolism
Pofi, R., Alcubierre, D. D., Dong, J., & Tomlinson, J. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-071723-044849 · Cited by 6
Fleseriu, M., Castinetti, F., Gadelha, M. R., Giustina, A., Lacroix, A., Melmed, S. K., Newell-Price, J. D. C., Pivonello, R., Reincke, M., & Biller, B. M. K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00135-8 · Cited by 4
Self-citationKrzystek, Ł., Sagan, K. P., Andrysiak-Mamos, E., Retfiński, S., Buć, K., Marczak, W., Brzeska, A., Patalong-Wójcik, M., Żochowska, E., Dąbkowski, K., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1700273 · Cited by 3
Current and Emerging Pharmacological Therapies for Cushing's Disease
Divaris, E., Kostopoulos, G., & Efstathiadou, Z. A. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128290025240216110928 · Cited by 3
Katabami, T., Matsuba, R., Nagasaka, T., Yamamoto, Y., Sakai, K., & Sone, M. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0696 · Cited by 3
Li, L., & Zhao, W. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329088 · Cited by 4
“In contrast, other studies have indicated that diarrhea, hypokalaemia, muscle spasms, vomiting [7], arthralgia [8], decreased appetite [9], gamma-glutamyl transferase increase, nasopharyngitis [10], depression [11] are the most prevalent AEs.”
InfluentialCastro, M. A., García-Centeno, R., Aller, J., Marazuela, M., Soto, A., Gálvez, M. A., Cámara, R., Valassi, E., Bernabéu, I., Villar‐Taibo, R., et al. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501654 · Cited by 5
Borawski, B., Wojciechowska-Luźniak, A., Zieliński, G., & Witek, P. (2023) · Endokrynologia Polska · doi:10.5603/ep.a2023.0038 · Cited by 3
Self-citationHamidi, O., St-Jean, M., Lacroix, A., & Bancos, I. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag095 · Cited by 5
Osilodrostat Treatment for Cushing Syndrome: 5 Years on Since Regulatory Approval
Yuen, K. C. J. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.005 · Cited by 3
Enhanced Radiological Detection of a Corticotroph Adenoma Following Treatment With Osilodrostat
Htut, Z., Yang, L., MacFarlane, J., Gillett, D., Gurnell, M., & Wernig, F. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf200 · Cited by 3
“These outcomes were observed in both microadenomas and macroadenomas, with no clear correlation to treatment duration or osilodrostat dose [20].”
Aldosterone synthase inhibitors in cardio-renal diseases: a state-of-the-art review
Dawood, M. H., Khan, M., Rashid, A. M., & Haverkamp, W. (2025) · Global Cardiology · doi:10.4081/cardio.2025.91 · Cited by 4
Castinetti, F., Bertherat, J. Y., Chanson, P., Raverot, G., Young, J., & Tabarin, A. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10020-1 · Cited by 4
“Based on the characteristics of the drug in the Summary of Product Characteristics (SmPC) ( h t t p s : / / w w w . e m a . e u r o p a . u / e n / m e d i c i n e s) and the doses given in LINC-3 and LINC-4 [20, 22 ], the usual first-line recommended dose is 2 mg BID.”
InfluentialInternational real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome
Araujo-Castro, M., Bancos, I., Detomas, M., Reincke, M., Salehi, M., Lu, H., Altieri, B., Kroiss, M., Oettle, M., Guerrero‐Pérez, F., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag115 · Cited by 1
Sasson, L., & Shimon, I. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag033 · Cited by 2
“These benefits parallel those reported in pervious trials where normalization of cortisol levels correlated with improvements in metabolic parameters and quality of life [2, 10, 11].”
InfluentialOsilodrostat Safety Profile: Findings from Real-World Data in the FAERS Database
Ilie, I. R. P., Butucă, A., Homorodean, C., Dobrea, C. M., Morgovan, C., Frum, A., & Ghibu, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103518 · Cited by 3
“Nevertheless, these findings offer valuable insights and a foundation for future, more comprehensive safety assessments.”
Salvio, G., Ciarloni, A., Aboud, N., Ambo, N., Bordoni, M., Lucchetti, B., Martino, M., Perrone, M., Gasparroni, M., Balercia, G., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf681 · Cited by 2
New Trends in Treating Cushing’s Disease
Violetis, O., & Alexandraki, K. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.2.3 · Cited by 2
Serum Cortisol and Cardiovascular Disease Risk - A Potential Biomarker
Oo, W. J., Lim, C. L., Goh, M. H., & Koh, R. Y. (2025) · Current Cardiology Reviews · doi:10.2174/011573403x328499241106064553 · Cited by 3
“One 11-β hydroxylase inhibitor that has been found effective in decreasing cortisol levels upon going through phases of clinical trials is osilodrostat [95-97].”
Medical Therapies of Cushing’s Disease–Part 1
Schwarz, Y., Nowak, E., Halperin, R., Shah, S., Agrawal, N., & Feelders, R. A. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2025.08.002 · Cited by 2
Self-citationReal-life data on pasireotide in monotherapy or combined in active Cushing’s disease
Mondin, A., Ceccato, F., Scaroni, C. M., Denaro, L., Manara, R., Robertazzo, U. M., & Barbot, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1695342 · Cited by 2
“The add-on was performed after a median of 5 [3; 10] months of pasireotide therapy and was carried out for a median duration of 22 [2; 54.5] months with dosages detailed in Table 2.”
InfluentialControlling cortisol excess and comorbidities in Cushing’s syndrome with osilodrostat
Fleseriu, M., Newell-Price, J. D. C., Gadelha, M. R., & Biller, B. M. K. (2025) · Pituitary · doi:10.1007/s11102-025-01605-1 · Cited by 2
“Despite theoretical concerns regarding accumulation of mineralocorticoid precursors, new or worsening hypertension and hypokalemia were uncommon in clinical studies of osilodrostat [2, 4 , 8].”
Self-citationOsilodrostat for the treatment of Cushing syndrome: an update
Działach, Ł., & Witek, P. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2615346 · Cited by 2
“Overall, 11.0% of patients discontinued treat-ment, primarily due to AEs or decisions made by the patient or physician [12].”
InfluentialSelf-citationAldosterone synthase inhibitors in hypertension and chronic kidney disease: double the benefit?
Mazzieri, A., Battistoni, S., & Reboldi, G. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001175 · Cited by 1
Kanzawa, M., Maeda, T., Ohta, Y., Ohno, Y., Nakamura, Y., & Chihara, K. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag093 · Cited by 1
“Osilodrostat, a potent oral inhibitor of 11 β -hydroxylase (CYP11B1), is highly effective in suppressing cortisol production and is widely used to manage Cushing disease [3].”
Gilis‐Januszewska, A., Gamrat-Żmuda, A., Minasyan, M., Więcławek, M., & Hubalewska–Dydejczyk, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1866631 · Cited by 1
“As demonstrated in the LINC-3 and LINC-4 studies (34, 35, 51 – 53), a decrease in cortisol levels translates directly into metabolic improvement.”
Self-citationEfficacy and safety of osilodrostat in patients with ectopic Cushing’s syndrome
Castro, M. A., Arroyo-Ripoll, O. F., Contreras-Saldarriaga, J. E., & Biagetti, B. (2026) · HORMONES · doi:10.1007/s42000-026-00806-y · Cited by 1
Tabarin, A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac268 · Cited by 1
“…normalization of UFC does not represent ideal control of the disease as it may be associated with a persistently disrupted circadian rhythm of cortisol secretion as reflected by normalization of late-night salivary cortisol (LNSC) in less than half of the patients with controlled UFC (3, 4).”
InfluentialPharmacotherapy for Cushing disease: a recent Australian experience with osilodrostat
Fookeerah, P., & McLean, M. P. (2023) · Internal Medicine Journal · doi:10.1111/imj.16038 · Cited by 1
Kamińska, M., Strzoda, A. J., Agata, J. U. D. A., Rojek, K., Strzoda, A., Sowiński, W., & Polak, A. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.01.030
“(15) Also at least one physical feature of CS such as central obesity (moon face), muscle atrophy of the limbs, red stretch marks and facial plethora has improved in over 25% of examined, buffalo hump improvement was observed in over 50% of patients during Osilodrostat treatment.”
BackgroundTerapia medica della Sindrome di Cushing: aggiornamenti su Osilodrostat
Morelli, V., & Favero, V. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01212-x
What newly brought endocrinology by the past 2022?
Mel'nichenko, G. A., & Shestakova, M. V. (2023) · Problems of Endocrinology · doi:10.14341/probl13261
Steroidogenesis inhibitors in the treatment of nonoperative Cushing’s syndrome – a literature review
Kamińska, M., Strzoda, A. J., Strzoda, A., Strzoda, A., Sowiński, W., Zdybel, M., Agata, J. U. D. A., Rojek, K., & Polak, A. (2023) · Family Medicine & Primary Care Review · doi:10.5114/fmpcr.2023.127682 · Cited by 1
Efficacia e sicurezza di osilodrostat nella sindrome di Cushing da produzione ectopica di ACTH
Brunetti, A., & Lania, A. G. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01367-7
Hipertensión arterial secundaria a Enfermedad de Cushing. Reporte de caso
Garay García, K. J., Flores Enderica, C. G., Andrade Sandoval, E. A., & Moreno Sierra, W. M. (2024) · doi:10.36015/cambios.v23.n1.2024.967 · Cited by 1
Pituitary tumors, ACTH-secreting
Pivonello, R., Larocca, A., Simeoli, C., Paola, N. D., Crescenzo, E. M., & Colao, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00122-9
Uso dell’osilodrostat: dagli studi LINC alla real world nelle sindromi di Cushing da ACTH ectopico
Ceccato, F., Richiusa, R., Sardone, D., & Bernardi, S. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01621-0
Kumar, S., Rawat, A., Sanapala, K., Alisha, K. A., Dhall, S., Prajapati, S. D., Patel, M. K., Das, A., Ramteke, H. D., & Khan, R. (2025) · medRxiv · doi:10.1101/2025.09.01.25334840
Tsoli, M., Bel-Ange, A., Atlan, K., Ben‐Haim, S., Kaltsas, G., & Grozinsky‐Glasberg, S. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01354-0
“Osilodrostat is a recently developed inhibitor of 11-β hydroxylase with improved potency and longer half-life than metyrapone, and is well-tolerated in phase III trials including patients with Cushing’s disease [69, 70].”
Ishikawa, T., Sawagashira, R., Ito, H., Kameda, H., & Kato, T. A. (2025) · Cureus · doi:10.7759/cureus.96607
Castro, M. A., García-Centeno, R., Aller, J., Marazuela, M., Soto, A., Gálvez, M. A., Cámara, R., Valassi, E., Bernabéu, I., Villar‐Taibo, R., et al. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501654 · Cited by 2
Metadata
- Authors
- Gadelha, M., Bex, M., Feelders, R. A., Heaney, A. P., Auchus, R. J., Gilis-Januszewska, A., Witek, P., Belaya, Z., Yu, Y., Liao, Z., Ku, C. H. C., Carvalho, D., Roughton, M., Wojna, J., Pedroncelli, A. M., & Snyder, P. J.
- Affiliations
- Universidade Federal do Rio de Janeiro (BR)
- Universitair Ziekenhuis Leuven (BE)
- Erasmus MC (NL)
- University of California, Los Angeles (US)
- University of Michigan (US)
- Department of Endocrinology, Jagiellonian University Medical College , Kraków , Poland
- Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw , Warsaw , Poland
- Endocrinology Research Center (RU)
- West China Hospital of Sichuan University (CN)
- Sun Yat-sen University (CN)
- Clinica Los Yoses , San Pedro , Costa Rica
- Universidade do Porto (PT)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- Recordati AG , Basel , Switzerland
- University of Pennsylvania (US)
- Corresponding author
- Gadelha, Mônica
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2022-03-23
- Volume
- 107
- Issue
- 7
- Pages
- e2882-e2895
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC9202723
- OpenAlex
- W4220667260
- Semantic Scholar
- 71c848803fb3dd5777e985b42b03be3daabfc26c
- Cited by
- 114
- References
- 19
- Citations by year
- 2026: 24 · 2025: 38 · 2024: 18 · 2023: 22 · 2022: 12
- FWCI
- 16.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
- Funders
- Eli Lilly and Company
- Pfizer
- Neurocrine Biosciences
- Quest Diagnostics
- Recordati Rare Diseases
- Novo Nordisk
- H. Lundbeck A/S
- Ipsen
- Novartis Pharma
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- Cushing's disease, osilodrostat, 11β-hydroxylase inhibitor, hypercortisolism, cortisol suppression, urinary free cortisol, drug safety, adverse events, open-label extension, treatment efficacy, joint pain, appetite loss, nausea
- MeSH terms
- Adult, Double-Blind Method, Humans, Hydrocortisone, Imidazoles, Pyridines, Treatment Outcome, Pituitary ACTH Hypersecretion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.